The NHS screening programmes save thousands of lives annually but their impact depends critically on participation rates. Cervical screening participation has fallen from approximately 80% in 2009 to approximately 69% in 2022. GPs who integrate opportunistic screening promotion into every consultation make the greatest difference. The switch to HPV primary screening in England (completed 2019) increased sensitivity for CIN2+ from approximately 77% to approximately 95%. An HPV-negative smear has much stronger negative predictive value than cytology alone, justifying the longer recall interval of 3-5 years. The lung cancer targeted lung health check (TLHC) programme is now being rolled out nationally for heavy smokers aged 55-74 — annual low-dose CT reduces lung cancer mortality by approximately 20%.

The HPV primary screening workflow change: a sample tests for high-risk HPV first; HPV negative means very low cervical cancer risk and safe 3-5 year recall without cytology. HPV positive triggers reflex cytology on the same sample. HPV positive plus cytology negative = retest in 12 months (not discharge — monitoring required). HPV positive plus cytology abnormal = colposcopy referral. Approximately 15% of screened women are HPV positive. GPs should explain longer intervals are appropriate and safe because of higher sensitivity of HPV testing.

The NHS Health Check QRISK3 threshold for statin initiation is 10% 10-year cardiovascular risk (atorvastatin 20 mg — NICE recommends this as primary prevention threshold). The TLHC programme represents the most significant new cancer screening initiative since bowel scope — low-dose CT scanning detects lung cancers at stage I when curative surgery is feasible. GP practices in TLHC areas should run searches to identify eligible patients (COPD register, smoking status codes, age 55-74) and ensure they receive invitations. Universal MMR IHC on CRC resections for Lynch syndrome identification is now standard in NHS pathology — GPs receiving pathology results for CRC patients should check whether MMR testing was performed and if MMR deficient, refer to clinical genetics for Lynch syndrome germline testing.

The aspirin-Lynch syndrome CAPP2 trial result is one of the most important chemoprevention findings in genetic cancer medicine: daily aspirin 600 mg OD taken for a minimum of 2 years reduced CRC incidence in Lynch syndrome carriers by approximately 63% at 10-year follow-up (Burn et al., Lancet 2020). The effect took approximately 4-5 years to manifest (consistent with aspirin's mechanism of reducing early polyp formation and reducing microsatellite instability-driven mutagenesis). Current NICE guidance recommends discussing aspirin with Lynch syndrome patients. The dose (600 mg) is higher than standard cardiovascular aspirin dosing — gastric protection with a PPI is important. The CAPP3 trial is currently testing lower doses (100 mg and 300 mg) which may achieve similar CRC prevention with fewer GI side effects.

The colposcopy referral explanation is critical for patient wellbeing — approximately 50,000 colposcopies are performed annually in England. Approximately 60% show CIN1 or no significant lesion. Even CIN2/3 (requiring treatment) is pre-cancerous, not cancer. LLETZ treatment of CIN2/3 is curative in 95% and takes 15 minutes. The GP explanation that reduces anxiety: this referral is because the smear showed changes that need closer examination. Most women referred to colposcopy do not have cancer. The colposcopy allows us to identify and treat any changes before they ever become a problem.

The post-treatment cervical surveillance protocol after LLETZ for CIN2/3 is mandatory and frequently misunderstood: HPV test at 6 months post-treatment (test of cure). HPV negative at 6 months = return to 3-yearly or 5-yearly recall. HPV positive at 6 months = return to colposcopy. Do NOT discharge to routine recall immediately after treatment — post-treatment surveillance is mandatory. In some protocols, if HPV persists, annual testing continues for 10 years. GPs should code the LLETZ treatment on the clinical record so that the screening programme can apply the correct recall interval. Women who had treatment before 2012 (pre-HPV testing era) need to ensure they are on the correct enhanced surveillance pathway.

GPs can significantly improve population screening uptake through opportunistic promotion — research consistently shows that a recommendation from a trusted GP is the single most powerful motivator for screening participation. A brief statement during a consultation for an unrelated problem: 'I notice you are due for your cervical screening — would you like to book that today before you leave?' takes 15 seconds and has measurable impact on attendance rates. Practices that train all clinical and administrative staff to raise screening at every contact (not just clinicians) see significantly higher participation rates than those relying solely on postal invitations.

Cancer screening-related anxiety is a significant healthcare burden — studies show that women recalled after an abnormal mammogram have measurable psychological distress for up to 3 years even when cancer is excluded. The GP's communication style at the point of discussing screening results has a lasting impact on patient wellbeing. Key communication principles: acknowledge the anxiety explicitly (do not minimise it); provide accurate probabilistic information (most recalled patients do not have cancer); give a clear timeline for next steps; and offer a follow-up appointment specifically to discuss concerns. For patients where cancer is confirmed, the transition from screening to diagnosis is a critical point requiring empathetic communication, clear information about the MDT pathway, and active signposting to clinical nurse specialists and patient support organisations.

The clinical governance requirement for tracking screening referral outcomes is increasingly a CQC inspection priority — practices that cannot demonstrate systems for: (1) tracking abnormal screening results through to specialist review; (2) following up patients who do not attend their referral appointment; and (3) recording the outcome of the referral in the clinical record — are identified as having patient safety gaps. EMIS Health and SystmOne both have referral tracking modules that can be configured to flag outstanding referrals for clinical review. Practices should audit annually: how many abnormal screening results generated a referral, what proportion of those referrals have an outcome recorded, and how many patients did not attend and were not followed up.